Available EU DMF/CEP
EU DMF
CEP
API Status
Commercial
Pipeline
Therapeutic Category
Alimentary tract & metabolism
Anti-infectives for systemic use
Antipyretic, analgesic and anti-inflammatory
Antineoplastic & immunomodulating agents
Blood & blood forming organs
Cardiovascular system
Genito-urinary system & sex hormones
Injectable forms
Musculo-skeletal system
Nervous system
Opthalmological preparations
Respiratory system
Available US DMF
US DMF
Available Japanese/Chinese DMF
Japanese DMF
Chinese DMF
Korean DMF

Chlorpromazine hydrochloride*

CAS No.

69-09-0

Innovator/marketer

Largactil

Polymorphic form

Crystalline anhydrous form II

Therapeutic Area

Nervous system

Status

Pipeline

EU DMF readiness

Q4 2018

US DMF readiness

Q4 2018

Drug description:

Chlorpromazine hydrochloride is an anti-emetic and antipsychotic agent.
It is indicated for the treatment of schizophrenia, to control nausea and vomiting, for relief of restlessness and apprehension before surgery, acute intermittent porphyria, as an adjunct in the treatment of tetanus, to control the manifestations of the manic type of manic-depressive illness and for relief of intractable hiccups.
It is formulated as sugar coated tablets for oral route of administration.

Mechanism of action:

Chlorpromazine has depressant actions on the Central Nervous System, with alpha-adrenergic blocking and anticholinergic activities. It inhibits Dopamine and Prolactin release-inhibitory factor, thus stimulating the release of Prolactin. It increases the turnover of Dopamine in the brain. It has anti-emetic, anti-puritic, serotonin-blocking and weak anti-histamine properties and slight ganglion blocking activity. It inhibits the heat regulating center in the brain, and is analgesic and can relax skeletal muscle. Due to its action on the autonomic system it produces vasodilatation, hypotension and tachycardia. Salivary and gastric secretions are reduced.

* product not covered by a compound patent in the territory of Poland

DISCLAIMER
The above product is presented solely for informational purposes and does not constitute an offer in any sense. Products under patent (SPC) protection in Poland and/or other countries are not offered until expiration of the corresponding IP right.

OK